Page 148 - 2020_07-Haematologica-web

G. Cario et al.
after HSCT (for details see Online Supplementary Figure S1). Altogether, 36 of 46 (78.3%) patients were treated in the HR group [(no-TKI 24 of 33 (72.7%)], TKI 12 of 13 (92.3%)), and HSCT in first CR was performed in 25 of 46
(54.3%) patients: in 16 of 33 (48.5%) of no-TKI and in 9 of 13 (69.3%) of TKI-treated patients (Table 1). Compared to theentiregroupofB-ALLpatientsoftheAIEOP-BFMALL 2000 study, ABL-class fusion positive cases were older and
Table 1. Patients' and clinical characteristics and response to treatment according to ABL-class fusion and tyrosine kinase inhibitor (TKI) treat- ment in comparison with the entire AIEOP-BFM 2000 B-ALL cohort.
ABL-class fusion pos cases Total
n (%)
Treatment without additional TKI1
Treatment with additional TKI
ALL-BFM 2000 B-ALL
Total n (%)
P2
n.s.
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
All n (%)
PDGFRB ABL1 fusion fusion n(%) n(%)
Others3 n (%)
All n (%)
PDGFRB ABL1 fusion fusion n(%) n(%)
Others n (%)
N. of patients
Sex
Male
Female
Age at diagnosis (years)
0–9
>10
WBC count4 (x109/L)
Lower than 50 50-<100
100 or higher
No information NCI Risk group5
SR
HR
No information
Pred. response6
Good
Poor
No information
MRD7 at End of induction ≥5x10-2
5x10-4-<5x10-2
<5x10-4
No information
Treatment group SR
IR HR
No information
HSCT8
No
Yes
46 (100.0) 33 (100.0) 17 (100.0) 10 (100.0) 6 (100.0) 13 (100.0) 6 (100.0) 5 (100.0) 2 (100.0) 3854 (100.0)
29 (63.0)
17 (37.0)
22 (47.8) 24 (52.2)
16 (34.8) 9 (19.6) 19 (41.3) 2 (4.3)
7 (15.2) 37 (80.4) 2 (4.3)
22 (47.8) 23 (50.0) 1 (2.2)
22 (47.8) 8 (17.4) 12 (26.1) 4 (8.7)
9 (19.6) 12 (26.1) 20 (43.5) 5 (10.9)
3 (6.5) 5 (10.9) 36 (78.3) 2 (4.3)
21 (45.7)
25 (54.3)
22 (66.7)
11 (33.3)
15 (45.5) 18 (54.5)
14 (42.4) 7 (21.2) 12 (36.4) 0
7 (21.2) 26 (78.8) 0
17 (51.5) 16 (48.5) 0
17 (51.5) 5 (15.2) 9 (27.3) 2 (6.1)
8 (24.2) 9 (27.3) 15 (45.5) 1 (3.0)
3 (9.1) 4 (12.1) 24 (72.7) 2 (6.1)
17 (51.5)
16 (48.5)
12 (70.6)
5 (29.4)
7 (41.2) 10 (58.8)
8 (47.1) 4 (23.5) 5 (29.4) 0
3 (17.6) 14 (82.4) 0
5 (29.4) 12 (70.6)
13 (76.5) 2 (11.8) 1 (5.9) 1 (5.9)
5 (29.4) 8 (47.1) 3 (17.6) 1 (5.9)
0
0
17 (100.0) 0
5 (29.9)
12 (70.1)
7 (70.0)
3 (30.0)
7 (70.0) 3 (30.0)
4 (40.0) 2 (20.0) 4 (40.0) 0
3 (30.0) 7 (70.0) 0
9 (90.0) 1 (10.0) 0
1 (10.0) 3 (30.0) 6 (60.0) 0
1 (10.0) 0
9 (90.0) 0
2 (20.0) 3 (30.0) 3 (30.0) 2 (20.0)
10 (100.0)
0
3 (50.0)
3 (50.0)
1 (16.7) 5 (83.3)
2 (33.3) 1 (16.7) 3 (50.0) 0
1 (16.7) 5 (83.3) 0
3 (50.0) 3 (50.0) 0
3 (50.0) 0
2 (33.3) 1 (16.7)
2() 1 (16.7) 3 (33.3) 0
1 (16.7) 1 (16.7) 4 (66.7)
7 (53.8)
6 (46.2)
6 (46.2) 7 (53.8))
2 (15.4) 2 (15.4) 7 (53.8) 2 (15.4)
3 (50.0)
3 50.0)
1 (16.7) 5 (83.3)
2 (33.3) 1 (16.7) 3 (50.0) 0
3 (60.0)
2 (40.0)
4 (80.0) 1 (20.0)
0
1 (20.0) 3 (60.0) 1 (20.0)
0
4 (80.0) 1 (20.0)
3 (60.0) 1 (20.0) 1 (20.0)
1 (20.0) 1 (20.0) 3 (60.0) 0
1 (20.0) 0
3 (60.0) 1 (20.0)
1 (50.0)
1 (50.0)
1 (50.0) 1 (50.0)
0
0
1 (50.0) 1 (50.0)
1 (50.0) 1 (50.0)
1 (50.0) 1 (50.0) 0
1 (50.0) 0
1 (50.0)
0
1 (50.0)
2062 (53.5)
1792 (46.5)
2999 (77.8) 855 (22.2)
3288 (85.3) 325 (8.4) 241 (6.3) 0
2574 (66.8) 1280 (33.2) 0
3619 (93.9) 214 (5.6) 21 (0.5)
86 (2.2) 610 (15.8) 2925 (75.9) 233 (6.0)
34 (0.9) 151 (3.9) 3452 (89.6) 217 (5.6)
1337 (34.7) 2088 (54.2) 429 (11.1) 0
3684 (95.1)
216 (4.9)
MRD after consolidation
2 (15.4)
5 (38.5) 7 (53.8) 1 (7.7)
5 (38.5) 3 (23.1) 3 (23.1) 2 (15.4)
1 (7.7) 3 (23.1) 5 (38.5) 4 (30.8)
0
1 (16.7) 5 (83.3)) 0
4 (66.6) 1(16.7) 0
1 (16.7)
0
2 (33.3) 2 (33.3) 2 (33.3)
≥5x10-2 5x10-4-<5x10-2 <5x10-4
No information
1 (50.0) 0000
00 11(84.6) 6(100.0)
1 (7.7) 0 1 (20.0) 12(92.3) 6(100.0) 4 (80.0)
0
2 (100.0)
0
2 (100.0)
0000
2 (33.3)
4 (66.7)
4 (30.7)
9 (69.3)
1 (16.7)
5 (83.3)
3 (60.0)
2 (40.0)
ALL: acute lymphoblastic leukemia. 1TKI: tyrosine kinase inhibitor. 2Fisher test comparing all ABL-class positive cases to the B-ALL AIEOP-BFM 2000 cohort, patients with no infor- mation excluded from test. 3Others: ABL2 n=5, CSFR1 n=3. 4WBC: white blood cell count. 5NCI-SR,WBC <50x109/L and age <10 years; NCI-HR,WBC >50x109/L and/or age >10 years. 6Good: <1,000 leukemic blood blasts / μL on treatment day 8, poor: more than 1000 /μL. 7MRD: minimal residual disease. 8HSCT: hematopoietic stem cell transplantation.
1890
haematologica | 2020; 105(7)